Clinical Trial Update: Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma [NA]

View source ↗

Summary

A clinical trial update on a three-drug combination (Sintilimab, Chidamide, and Azacitidine) for untreated Stage I–II Extranodal NK/T-cell lymphoma, with status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Chidamide (chidamide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Complete Remission Rate， CRR, Progression Free Survival | NA | Status: NOT_YET_RECRUITING